Krsnaa Diagnostics recommends ₹2/share final dividend; approves FY26 results
Krsnaa Diagnostics approved FY26 audited financial results. Recommended a final dividend of ₹2 per equity share for FY26. Recommended appointment of M/s Kirtane & Pandit LLP as Statutory Auditors for FY27-FY31. Consolidated PAT was ₹1,014.31 million and standalone PAT was ₹1,026.75 million.
The declaration of a dividend and the approval of financial results are standard corporate actions. The appointment of auditors is also a routine but important governance matter. The impact is medium as it relates to financial performance and governance.
The recommendation of a final dividend and approval of financial results, coupled with the reappointment of auditors, are positive developments for the company.
Krsnaa Diagnostics Limited announced that its Board of Directors, at a meeting held on May 25, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The company recommended a final dividend of ₹2 per equity share (40% of face value) for the financial year 2025-26, subject to shareholder approval at the upcoming Annual General Meeting (AGM).
Additionally, the Board recommended the appointment of M/s Kirtane & Pandit LLP as Statutory Auditors for FY 2026-27 to FY 2030-31, subject to shareholder approval. M/s Mahajan & Aibara Chartered Accountants LLP were re-appointed as Internal Auditors, Harshad S. Deshpande & Associates as Cost Auditors, and M/s V. A. Dudhedia and Co. as Tax Auditors for FY 2026-27 (for Tax Auditors, FY 2025-26).
The financial results for the year ended March 31, 2026, showed a consolidated profit after tax of ₹1,014.31 million (₹101.43 crore) and standalone profit after tax of ₹1,026.75 million (₹102.68 crore). Revenue from operations for the year stood at ₹7,727.74 million (₹772.77 crore) consolidated and ₹6,909.47 million (₹690.95 crore) standalone.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under dividend. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.